Loading
Life sciences · Review
Jeadv Clinical Practice · August 17, 2026
Well-designed and adequately powered for the question it asks.
This meta-analysis of 14 studies demonstrates that vitiligo is associated with lower odds of melanoma and non-melanoma skin cancers overall, with a statistically significant 24% reduction in squamous cell carcinoma risk. Phototherapy exposure showed numerically higher but non-significant cancer risk point estimates, providing a benchmark for baseline cancer risk assessment in vitiligo patients.
Systematic review and meta-analysis. Studies comparing skin cancer incidence (melanoma and non-melanoma skin cancers) in patients with vitiligo versus matched or unmatched controls; specific eligibility criteria not detailed in abstract.. Intervention: Vitiligo (disease status) and phototherapy exposure (subgroup analysis).. Compared with: Absence of vitiligo (control groups); no phototherapy exposure (in phototherapy subgroup analysis).. n = 454,307. Not specified in abstract..
Vitiligo associated with lower odds of melanoma: OR 0.43 (95% CI 0.16–1.13), though CI includes unity. Squamous cell carcinoma risk significantly reduced in vitiligo: OR 0.76 (95% CI 0.57–0.99; p = 0.045). Non-melanoma skin cancer overall showed inverse trend: OR 0.29 (95% CI 0.06–1.49), with wide CI.
Safety was not reported in the material analysed. Check the source before drawing any conclusion about harm.
Clinicians should be aware that vitiligo appears to confer a protective effect against skin cancer, particularly squamous cell carcinoma, which may reassure patients and inform baseline risk counselling. The non-significant higher point estimates for phototherapy exposure warrant continued safety monitoring, although the wide confidence intervals prevent firm conclusions about phototherapy's incremental cancer risk.
Rigorous systematic review and meta-analysis of 14 studies with 454,307 vitiligo patients demonstrating statistically significant inverse association with squamous cell carcinoma and consistent inverse trends for melanoma and overall NMSC, though with wide confidence intervals.
As stated by the source record.
Quoted from the source exactly as published.
Clinicians should be aware that vitiligo appears to confer a protective effect against skin cancer, particularly squamous cell carcinoma, which may reassure patients and inform baseline risk counselling. The non-significant higher point estimates for phototherapy exposure warrant continued safety monitoring, although the wide confidence intervals prevent firm conclusions about phototherapy's incremental cancer risk.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
ABSTRACT Background Vitiligo is an autoimmune disorder characterized by CD8+ T cell‐mediated melanocyte destruction and a pro‐inflammatory immune milieu. Despite frequent use of ultraviolet‐based phototherapy, emerging evidence suggests that vitiligo may paradoxically confer a reduced risk of skin cancer. Clarifying this association may provide insight into tumor immune surveillance and inform risk assessment in patients with vitiligo. Objectives To evaluate the association between vitiligo and the risk of melanoma and non‐melanoma skin cancers (NMSC), and to assess the potential impact of phototherapy exposure on skin cancer risk. Methods A PRISMA‐compliant systematic review and meta‐analysis searched PubMed, Scopus, Embase, and ClinicalTrials.gov through January 2026 for studies comparing skin cancer incidence in patients with vitiligo versus controls. Pooled odds ratios (ORs) with 95% confidence intervals (CIs) were calculated using Hartung‐Knapp random‐effects models, with assessment of heterogeneity and publication bias. Results Fourteen studies were included (454,307 vitiligo patients; 3,583,147 controls), of which nine were eligible for meta‐analysis. Vitiligo was associated with lower odds of melanoma (OR 0.43; 95% CI, 0.16–1.13), with consistent inverse associations across sensitivity analyses. A similar inverse trend was observed for NMSC overall (OR 0.29; 95% CI, 0.06–1.49). Squamous cell carcinoma risk was significantly reduced (OR 0.76; 95% CI 0.57–0.99; p = 0.045), while basal cell carcinoma showed a non‐significant inverse association (OR 0.54; 95% CI, 0.26–1.11). Phototherapy exposure was associated with higher point estimates for melanoma (OR 1.87; 95% CI 0.53–6.54) and NMSC (OR 1.46; 95% CI, 0.37–5.69), although neither association reached statistical significance. Funnel plots and Egger's testing did not detect publication bias. Conclusions Vitiligo was associated with lower odds of melanoma and NMSC, with a statistically significant reduction for squamous cell carcinoma. Phototherapy exposure showed higher but non‐significant point estimates. These findings provide a benchmark for baseline cancer risk in vitiligo and may inform safety monitoring of phototherapy and emerging immunomodulatory therapies. PROSPERO number: CRD42024619708.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.